Genenta Science SpA Sponsored ADR ( (GNTA) ) has issued an announcement.
On March 19, 2025, Genenta Science announced a €20 million financing through a mandatory convertible bond issued to ENEA Tech and Biomedical (ETB). This investment aims to expand Genenta’s pipeline, particularly advancing the Temferon™ cell therapy in metastatic Renal Cell Cancer. The financing structure includes two tranches, with the first tranche supporting the ongoing Phase 1/2a trial for mRCC. This strategic move is expected to provide necessary capital for achieving key milestones without immediate shareholder dilution. The announcement highlights promising survival rates in Genenta’s ongoing Glioblastoma Multiforme trial, with a noted increase in patient survival at two years. This development strengthens Genenta’s position in the immuno-oncology field and underscores its potential for strategic collaborations.
More about Genenta Science SpA Sponsored ADR
Genenta Science S.p.A. is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapies for solid tumor cancers. Their leading product candidate, Temferon™, is designed to deliver immune-therapeutic payloads within the tumor microenvironment, potentially enhancing immune responses and breaking immune tolerance. Genenta is advancing clinical trials for Glioblastoma Multiforme and metastatic Renal Cell Carcinoma, aiming to improve cancer treatment outcomes.
YTD Price Performance: -16.11%
Average Trading Volume: 10,999
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $69.5M
Find detailed analytics on GNTA stock on TipRanks’ Stock Analysis page.